Page 14 - Aurobindo Pharma

Aurobindo Pharma faces class action suit in US for concealing facts

Aurobindo Pharma allegedly concealed facts about cancer-causing agent NDMA in type-2 diabetes drug metformin

Aurobindo Pharma's debt pain recedes after calling off deal with Sandoz

Aurobindo was scheduled to acquire the portfolio with an upfront purchase price of $900 million in cash

Aurobindo Pharma gains 12% after USFDA issued EIR for Hyderabad facility

The stock is trading higher for the fourth straight day and has rallied 38 per cent during the period.

Aurobindo Pharma slips 17% as USFDA revokes VAI status for Unit-IV

Currently, Unit 4 has 15 abbreviated new drug applications (ANDA) approvals pending over the next one year.

US FDA revokes EIR issued to Aurobindo Pharma's Unit IV facility

On February 18, the US FDA issued the EIR with voluntary action indicated for Aurobindo Pharma's Unit IV injectable formulations unit

USFDA nod to Unit IV a breather for Aurobindo Pharma; share price up 20.4%

Analysts remain positive on Aurobindo's future prospects including the US despite the higher base

Aurobindo Pharma soars 19% as Unit IV receives EIR with VAI status from FDA

The Company has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from the US Food & Drug Administration (USFDA) for Unit IV.

Aurobindo Pharma gains 5% post December quarter results

The stock of the drug company was trading higher for the fifth straight day, up 14 per cent, against a 4 per cent rise in the S&P BSE Sensex during the period.

Aurobindo Pharma Q3 net marginally down at Rs 705 cr, revenue up 12%

According to a filing with the bourses, revenues from operations during the quarter under review was up by nearly 12 per cent to Rs 5,895 crore. It was Rs 5,269.7 crore in Q3 FY19.

Aurobindo Pharma Q3 PBT rises 6% to Rs 942.8 cr; revenues up 11.9%

The formulations revenues for the quarter posted a growth of 17.4 per cent year-on-year at Rs 5,104 cr

Aurobindo's oral solid formulations unit under USFDA scrutiny

The company in a filing on Thursday said the OAI classification will not have any material impact on the existing revenues or the supplies to its US business at this juncture

Aurobindo Pharma plunges 8% as USFDA classifies oral solids plant as OAI

USFDA, that had conducted a Current Good Manufacturing Practice (cGMP) inspection at the company's Unit 7 an oral solids formulation manufacturing facility from Sept 19-27, 2019, issued 7 observations

Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Ramco Cements

Currently, Ramo Cements' stock is hovering in a range, after a sharp up move, offering fresh buying opportunity to those who missed the chance earlier

Pharma shares in focus; Dr Reddy's, Divi's, Granules hit 52-week highs

Lupin, Sun Pharmaceutical, Cadila Healthcare, Aarti Drugs and Aurobindo Pharma were up in the range of 2 per cent to 3 per cent.

Aurobindo Pharma recalls Mirtazapine tablets in US over label error

The product is being recalled due to a label error on declared strength

AuroMedics Pharma recalls over 59000 vials of antipsychotic injection in US

The product was distributed to major wholesalers/distributors who may have further distributed the product throughout the US, it added

Aurobindo recalls heartburn drug ranitidine, two others from US market

Development follows regulatory compliance issues being faced by several of its plants back home; Ranitidine taken off due to the presence of carcinogenic compound

Aurobindo Pharma arm to buy certain biz assets of Profectus BioSciences

Aurobindo Pharma on Thursday said its subsidiary Auro Vaccines LLC has entered into a pact to acquire certain business assets from Profectus BioSciences Inc USA for an upfront cash consideration of USD 11.29 million (around Rs 80 crore) with potential earn-outs on achieving certain milestones. Auro Vaccines LLC is a wholly-owned subsidiary of Aurobindo Pharma USA Inc, USA, which is a wholly-owned arm of the company, Aurobindo Pharma said in a filing to the BSE. The indicative time period for completion of acquisition of research and development assets of Profectus BioSciences Inc is first half of 2020, it added. The acqusition provides access to proprietary and innovative technology platforms for prophylactic use and therapeutic use along with global R&D center, Aurobindo Pharma said. The acquisition will lead to enhancement of research and development capabilities and expertise in developing newer vaccines from basic discovery research into FDA-approved product, it added. Shares

Aurobindo Pharma aims to become debt-free in the next three years

The company's net debt decreased by $71 million quarter-on-quarter to $522 million at the end of September 2019 against $593 million at the end of June 2019

USFDA observes major protocol lapses in Aurobindo's sterile drug unit

Regulator issues Form 483 with as many as 14 observations that could impact ongoing operations at the plant